| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 05/04/2005 | CN1199946C Specific indole compound and its preparation and use in treating and preventing cancers |
| 05/04/2005 | CN1199678C Medicament for curing lithiasis |
| 05/04/2005 | CN1199645C Application of N-acetyl-D-aminoglucose in the preparation of medicine for treating urogenital system infection |
| 05/03/2005 | US6887998 Process for 8-carboxamido-2,6-methano-3-benzazocines |
| 05/03/2005 | US6887996 Compounds and their use |
| 05/03/2005 | US6887905 Treatment of depression or generalized anxiety disorder |
| 05/03/2005 | US6887903 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them |
| 05/03/2005 | US6887894 Use of lipoic acid for improving the bioavailability of mineral salts |
| 05/03/2005 | US6887870 Useful as antianginal and cardioprotective agents; for therapy and prophylaxis of angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia |
| 05/03/2005 | US6887869 Mikanolide derivatives, their preparation and therapeutic uses |
| 05/03/2005 | US6887865 N-heterocyclic derivatives as NOS inhibitors |
| 05/03/2005 | US6887844 To stimulate the proliferation or/and the outgrowth from cells presenting the neural cell adhesion molecule (NCAM) |
| 05/03/2005 | US6887472 That do not cause anaphylaxis, antigenic fusion proteins of given amino acid sequence, of a CH3 domain of an immunoglobulin (IgE) molecule; allergy vaccines; vaccine test methods in dogs |
| 05/03/2005 | CA2347950C Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction |
| 05/03/2005 | CA2147623C Novel p-selectin ligand protein |
| 04/28/2005 | WO2004075893A8 Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin ii receptor blocker |
| 04/28/2005 | WO2004014844A3 Aryl and heteroaryl compounds and methods to modulate coagulation |
| 04/28/2005 | WO2004014842A8 Acylated arylcycloalkylamines and their use as pharmaceuticals |
| 04/28/2005 | WO2003099201A3 Compositions and methods of use for a fibroblast growth factor |
| 04/28/2005 | WO2003044170A3 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use |
| 04/28/2005 | US20050090669 Aminoalcohol derivatives as beta-3 adrenergic receptor agonists |
| 04/28/2005 | US20050090555 Compound for the treatment of metabolic disorders |
| 04/28/2005 | US20050090536 Substituted pyrrol-3-ylisoxazoles, e.g., N-benzyl-4-[4-(o-chlorophenyl)-5-isoxazolyl)pyrrole-2-carboxamide; treating diseases that are alleviated by a protein kinase inhibitor, particularly cancer, inflammatory disorders, restenosis, and cardiovascular disease. |
| 04/28/2005 | US20050090524 Novel adamantane derivatives |
| 04/28/2005 | US20050090519 1-Alkyl-4-(3-substitutedphenyl)piperidines |
| 04/28/2005 | US20050090513 Compounds specific to adenosine a1 and a3 receptors and uses thereof |
| 04/28/2005 | US20050090503 5-HT receptor ligands and uses thereof |
| 04/28/2005 | US20050090493 Useful as anti-cancer agents; exhibit apoptotic effect in a warm-blooded animal such as man; for example, 2-{4-[3-(N,N-Dimethyl)amino-2-hydroxy-propoxy]anilino}-4-(2,4-difluoro-(N-cyanomethyl)anilino)pyrimidine |
| 04/28/2005 | US20050090491 2'-Methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 04/28/2005 | US20050090472 Xanthine oxidase inhibitors |
| 04/28/2005 | US20050090457 Method of treating mammals with genistein and/or genistein analogues |
| 04/28/2005 | US20050090000 Novel human 7TM protein and polynucleotides encoding the same |
| 04/28/2005 | US20050089911 87 human secreted proteins |
| 04/28/2005 | US20050089868 Modulators of tissue regeneration |
| 04/28/2005 | US20050089866 Identifying modulators for the treatment and prevention of diabetes, pain, obesity, nervous system, inflammatory, cell proliferative and liver disorders |
| 04/28/2005 | US20050089575 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof |
| 04/28/2005 | CA2542290A1 Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof |
| 04/27/2005 | EP1526134A2 Triazolyl tropane derivatives as ccr5 modulators |
| 04/27/2005 | EP1525889A1 Liquid pharmaceutical composition containing an erythropoietin derivative |
| 04/27/2005 | EP1525886A1 Absorbent for oral administration, and agent for treating or preventing renal or liver disease |
| 04/27/2005 | EP1525883A1 Ciclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 04/27/2005 | EP1525201A1 Bicyclic piperidine derivatives as antagonists of the ccr1 chemokine receptor |
| 04/27/2005 | EP1525200A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| 04/27/2005 | EP1525198A2 Acyloxypyrrolidine derivatives, preparation and therapeutic use thereof |
| 04/27/2005 | EP1524997A1 Stable liquid parenteral parecoxib formulation |
| 04/27/2005 | EP1524996A2 Combination of pde5 inhibitors with angiotensin ii receptor antagonists |
| 04/27/2005 | EP1524974A2 Transcription factor modulating compounds and methods of use thereof |
| 04/27/2005 | EP1524971A1 Improved transdermal delivery system |
| 04/27/2005 | EP1427430B1 Use of extracts of the genus cimicifuga as organoselective medicines for treating diseases of the genitourinary system caused by sex hormones |
| 04/27/2005 | EP1419150B1 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use |
| 04/27/2005 | EP1363614B1 Use of 2-amino-1-(4-hydroxy-3-methanesulphonamidophenyl)ethanol for treating urinary incontinence |
| 04/27/2005 | EP1325010B1 Substituted 3.4-dihydro-pyrimido [1,2-a]pyrimidines and 3.4-dihydropyrazino [1,2-a]pyrimidines |
| 04/27/2005 | EP1289519A4 Methods of treating androgen deficiency in men using selective antiestrogens |
| 04/27/2005 | CN1610676A Compounds and method for the treatment of overactive bladder |
| 04/27/2005 | CN1610674A Use of 2-amino-thiazoline derivatives as inhibitors of inducible NO-synthase |
| 04/27/2005 | CN1610668A Substituted propane-1, 3-diamine derivatives and the pharmaceutical use |
| 04/27/2005 | CN1610564A Compositions and methods of using collajolie |
| 04/27/2005 | CN1609105A 1-methylolimidazole [1, 2-alpha] quinoxaline compound and its application |
| 04/27/2005 | CN1608635A Compound concentrated vegetable oil for remitting male's prostatitis |
| 04/27/2005 | CN1608615A Fibrauretine-amino acid fluid for transfusion and its production process |
| 04/27/2005 | CN1608613A Fibrauretine powder for injection and its production process |
| 04/27/2005 | CN1198825C 8-pheyl-6,9-dihydro-[1,2,4]triazolo[3,4-i] purin-5-one derivatives |
| 04/27/2005 | CN1198818C Compound with growth hormone releasing properties |
| 04/27/2005 | CN1198793C Ethers of methyl venlafaxine |
| 04/27/2005 | CN1198628C Conditioned cell culture medium compositions and method of use |
| 04/27/2005 | CN1198608C Therapeutic and dietary compsns. containing essential fatty acids and bioactive disulphides |
| 04/27/2005 | CN1198607C Composition for treating or preventing glomerulopathy |
| 04/27/2005 | CN1198591C Bioenhanced formulations comprising eprosartan in oral dosage form |
| 04/26/2005 | US6884907 Containing carboxylic acid groups; diagnosis; prophylaxis |
| 04/26/2005 | US6884804 Inhibitors of Src and other protein kinases |
| 04/26/2005 | US6884801 Nitrogen compounds such as N-(4,5-dihydro-1H-imidazol-2-yl-methyl)-2-(methylsulfonyl)aniline, used for prophylaxis of incontinence |
| 04/26/2005 | US6884795 Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol |
| 04/26/2005 | CA2253871C Ret ligand (retl) for stimulating neural and renal growth |
| 04/26/2005 | CA2216810C Method for treatment of benign prostatic hypertrophy |
| 04/21/2005 | WO2005035536A1 Novel xanthone derivative, process for producing the same and pharmaceutical composition containing the same |
| 04/21/2005 | WO2005035534A1 Heterocyclic bicyclo ring and heterocyclic tricyclo ring compounds and drugs comprising the same |
| 04/21/2005 | WO2005035471A1 Ether derivative |
| 04/21/2005 | WO2005034986A1 Remedy for kidney diseases |
| 04/21/2005 | WO2005034970A1 Use of probiotic bacteria in the treatment of infection |
| 04/21/2005 | WO2004110995A8 N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors |
| 04/21/2005 | WO2004108119A3 Use of atp or derivatives in medicine |
| 04/21/2005 | WO2002092841A3 Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon |
| 04/21/2005 | US20050085639 Circulation disorders; antiproliferative agents; hypotensive agents; cardiovascular disorders; antiischemic agents; kidney disorders; atherosclerosis; restenosis; antiinflammatory agents; respiratory system disorders; angiogenesis inhibitors; anticancer agents; antiulcer agents |
| 04/21/2005 | US20050085542 Solution for peritomeal dialysis |
| 04/21/2005 | US20050085512 Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| 04/21/2005 | US20050085509 KInase inhibitors; antiarthritic agents; autoimmune diseases; sepsis; cachexia; Alzheimer's disease; antihistamines; thrombosis; glomerulonephritis; inflammatory bowel disorders; crohn's disese; multiple sclerosis; antitumor agents; skin disorders |
| 04/21/2005 | US20050085503 used for detecting diseases where N-acetylated alpha -linked acidic dipeptidase (NAALADase) levels are altered, effecting neuronal activity, effecting TGF- beta activity, inhibiting angiogenesis, and treating glutamate abnormalities, cancer, pain |
| 04/21/2005 | US20050085489 Pharmaceutical composition comprising a glitazone and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 04/21/2005 | US20050085476 Polymerase inhibitors; antiischemic agents; brain disorders; cardiovascular disorders; antiinflammatory agents; antiarthritic agents; neurodegenerative agents; Alzheimer's disease; muscular disorders; antidiabetic agents; kidney disorders; viricides; anticancer agents; immunosuppressants |
| 04/21/2005 | US20050085469 Fused bicyclic pyrimidine derivatives |
| 04/21/2005 | US20050084897 DNA encoding human vanilloid receptor VR3 |
| 04/21/2005 | US20050084489 Synergistic administration of Vitaxin, a FAB fragment, or a competitive binding antibody for binding integrin alpha V beta 3 with the enzyme inhibitor; antiinflammatory, anticarcinogenic agents; autoimmune and metabolic bone disorders |
| 04/21/2005 | US20050084476 Orally administering phosphate ion absorbent comprising as an active ingredient a weakly basic anion exchange resin, wherein resin is a copolymer containing as monomer components divinylbenzene and acrylamide or divinylbenzene and acrylate, wherein the copolymer further contains a tertiary amino group |
| 04/21/2005 | US20050084463 Antiinflammatory, antiarthritic agents, analgesics for pain caused by diabetic assoicated conditions, pneumoconiosis, angina, menstruation or cancer |
| 04/21/2005 | CA2541607A1 Therapeutic agents for renal diseases |
| 04/20/2005 | EP1524265A1 Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors |
| 04/20/2005 | EP1523994A1 Medicinal composition for regulating release and process for producing the same |
| 04/20/2005 | EP1523982A2 Plenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders |
| 04/20/2005 | EP1523556A1 Methods of treating conditions associated with an edg-1 receptor |
| 04/20/2005 | EP1523541A1 A process for decreasing environmental pollutants in an oil or a fat, a volatile environmental pollutants decreasing working fluid, a health supplement, and an animal feed product |